ReproCell

ReproCell Gross Profit

The Gross Profit of ReproCell (4978.T) as of Oct 9, 2026 is 1.01 B JPY. In the previous year, Gross Profit was 1.63 B JPY — a change of -37.90% (lower).

Gross Profit

1.01 BJPY

YoY

-37.90%

Last updated:

Gross Profit of ReproCell is 2026 1.01 B JPY. Gross Profit of ReproCell was 2025 1.63 B JPY. It decreases by -37.90% lower compared to the previous year.

The ReproCell Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2019
461.87 M JPY
Jan 1, 2020
433.27 M JPY
Jan 1, 2021
456.10 M JPY
Jan 1, 2022
785.42 M JPY
Jan 1, 2023
1.13 B JPY
Jan 1, 2024
1.10 B JPY
Jan 1, 2025
1.63 B JPY
Jan 1, 2026
1.01 B JPY
The ReproCell Gross Profit history
YEARGross ProfitYoY
1.01 BJPY-37.90%
1.63 BJPY+47.61%
1.10 BJPY-2.04%
1.13 BJPY+43.58%
785.42 MJPY+72.20%
456.10 MJPY+5.27%
433.27 MJPY-6.19%
461.87 MJPY+214.87%
146.69 MJPY-57.17%
342.52 MJPY+41.09%
242.77 MJPY-12.06%
276.05 MJPY+7.79%
256.10 MJPY+17.83%
217.35 MJPY+45.06%
149.84 MJPY+21.26%
123.57 MJPY+14.52%
107.90 MJPY+16.02%
93.00 MJPY+161.24%
35.60 MJPY—
Access this data via the Eulerpool API

ReproCell Revenue

ReproCell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.20 B JPY
-908.94 M JPY
-1.02 B JPY
Jan 1, 2021
1.29 B JPY
-1.05 B JPY
-812.57 M JPY
Jan 1, 2022
2.23 B JPY
-647.13 M JPY
-575.10 M JPY
Jan 1, 2023
2.95 B JPY
-356.22 M JPY
-305.31 M JPY
Jan 1, 2024
2.43 B JPY
-409.29 M JPY
-31.42 M JPY
Jan 1, 2025
2.98 B JPY
-130.41 M JPY
103.25 M JPY
Jan 1, 2026
2.23 B JPY
-860.06 M JPY
-591.69 M JPY
Jan 1, 2027 (e)
3.53 B JPY
203.78 M JPY
157.85 M JPY

ReproCell Margins

ReproCell stock margins

The ReproCell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ReproCell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ReproCell.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
36.11 %
-75.75 %
-84.72 %
Jan 1, 2021
35.46 %
-81.48 %
-63.17 %
Jan 1, 2022
35.15 %
-28.96 %
-25.74 %
Jan 1, 2023
38.18 %
-12.06 %
-10.34 %
Jan 1, 2024
45.52 %
-16.87 %
-1.29 %
Jan 1, 2025
54.74 %
-4.38 %
3.47 %
Jan 1, 2026
45.34 %
-38.51 %
-26.49 %
Jan 1, 2027 (e)
45.34 %
5.77 %
4.47 %

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Gross Profit of ReproCell is 1.01 B JPY in 2026.

Gross Profit of ReproCell changed from 1.63 B JPY to 1.01 B JPY, representing a -37.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit ReproCell since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's ReproCell historically and in real time.

Access this data via the Eulerpool API

Income Statement — ReproCell

All Key Metrics — ReproCell